MAIA (NYSE: MAIA) outlines 2026 Ateganosine cancer milestones

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. filed a current report to note that it issued a press release titled “MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines 2026 Clinical Milestones and Growth Momentum.” The release, attached as an exhibit, focuses on progress in the company’s Ateganosine cancer treatment program and its planned clinical milestones for 2026.

The report emphasizes that these updates are forward-looking statements and may differ from actual results. MAIA highlights key uncertainties, including the timing, cost and results of preclinical and clinical studies, the ability to advance product candidates through trials and regulatory review, manufacturing and commercialization efforts, market acceptance, market size and growth potential, and the ability to obtain and maintain intellectual property protection.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001878313 0001878313 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 20, 2026

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41455		83-1495913
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

444 West Lake Street, Suite 1700
Chicago, IL		60606
(Address of principal executive offices)		(Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MAIA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 20, 2026, MAIA Biotechnology, Inc. (the “Company”) issued a press release entitled “MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines 2026 Clinical Milestones and Growth Momentum” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward-looking Statements

The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated January 20, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 20, 2026

	MAIA BIOTECHNOLOGY, INC.
	By:	/s/ Vlad Vitoc
	Name:	Vlad Vitoc
	Title:	Chief Executive Officer

3

FAQ

What did MAIA (MAIA) disclose in this 8-K filing?

MAIA Biotechnology reported that it issued a press release titled “MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines 2026 Clinical Milestones and Growth Momentum.” The press release is attached as Exhibit 99.1.

What is the focus of MAIA Biotechnologys latest press release?

The press release focuses on advancing MAIAs Ateganosine cancer treatment program and outlining clinical milestones for 2026, along with comments on growth momentum.

Does this MAIA (MAIA) 8-K include detailed financial results?

No detailed financial results such as revenue or earnings are described in the text of this report. The primary purpose is to furnish the press release as an exhibit.

What key risks does MAIA highlight in its forward-looking statements?

MAIA notes risks related to timing, cost and results of studies, the ability to advance product candidates into and through clinical trials, the timing of regulatory filings and approvals, development, manufacturing and commercialization challenges, potential market acceptance and market size, and maintaining intellectual property protection.

Where can investors find the full details of MAIAs Ateganosine update?

Full details are included in Exhibit 99.1 to the report, which is the press release dated January 20, 2026 discussing the Ateganosine program, 2026 clinical milestones and growth momentum.

Does MAIA commit to updating these forward-looking statements?

MAIA states that any forward-looking statement speaks only as of its date and that the company undertakes no obligation to publicly update or revise such statements except as required by law.